Silence Therapeutics Plc Stock Investor Sentiment
| SLN Stock | USD 7.92 0.25 3.26% |
About 53% of Silence Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Silence Therapeutics PLC suggests that some traders are interested. Silence Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Silence Therapeutics PLC. Many technical investors use Silence Therapeutics PLC stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Silence |
Silence Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Silence Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Silence Therapeutics that are available to investors today. That information is available publicly through Silence media outlets and privately through word of mouth or via Silence internal channels. However, regardless of the origin, that massive amount of Silence data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Silence Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Silence Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Silence Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Silence Therapeutics alpha.
Silence Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Silence Therapeutics Sees Large Volume Increase - MarketBeat | 09/25/2024 |
2 | Silence Therapeutics files for ordinary shares offering | 10/22/2024 |
3 | Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | 11/14/2024 |
4 | BMO retains 67 target on Silence Therapeutics stock | 11/19/2024 |
5 | Silence Therapeutics Outperform Rating Reaffirmed at William Blair | 11/20/2024 |
6 | Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference | 11/26/2024 |
Check out Silence Therapeutics Hype Analysis, Silence Therapeutics Correlation and Silence Therapeutics Performance. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.429 | Quarterly Revenue Growth (0.93) | Return On Assets (0.22) | Return On Equity (0.64) |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.